Company Filing History:
8 out of 37 
2 out of 36 
1 out of 4 Years Active: 1999-2022
Title: Ulla Airaksinen: Innovator in Pharmaceuticals
Introduction
Ulla Airaksinen, an esteemed inventor based in Vantaa, Finland, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 12 patents, her work primarily focuses on modified beta-lactamases, which play a critical role in addressing challenges associated with antibiotic treatments.
Latest Patents
Among her latest inventions, Ulla's patent titled "Modified Beta-Lactamases and Methods and Uses Related Thereto" stands out. This invention encompasses novel recombinant beta-lactamases and pharmaceutical compositions that incorporate these innovative enzymes. The patent outlines methods for modifying and producing beta-lactamases, as well as treatments for preventing adverse effects from beta-lactam antibiotics. Additionally, it discusses the applications of beta-lactamases as medicaments and their use in manufacturing drugs aimed at mitigating antibiotic-induced side effects. Importantly, the invention also involves a specific polynucleotide and a host cell that contains it, further showcasing the depth of Ulla's research.
Career Highlights
Her career includes key positions at prominent companies such as Synthetic Biologics, Inc. and Xyrofin Oy, where she applied her expertise to drive innovative solutions in the pharmaceutical sector. Ulla's dedication to her work has played a role in advancing the understanding of beta-lactam antibiotics and their interactions within the body.
Collaborations
Throughout her career, Ulla has collaborated closely with notable colleagues, including Pertti Koski and Katja Valimaki. These partnerships have fostered a collaborative environment that is essential for driving innovation and furthering research in her field.
Conclusion
Ulla Airaksinen’s contributions to pharmaceuticals, particularly in modified beta-lactamases, demonstrate her commitment to innovation and improving health outcomes. As she continues to develop new methodologies and applications, her work is likely to have a lasting impact on antibiotic treatments and pharmaceutical advancements.